• Media type: E-Article
  • Title: Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer (OVHIPEC-1): Final Survival Analysis of a Randomised, Controlled, Phase 3 Trial
  • Contributor: Aronson, S. Lot; Lopez-Yurda, Marta; Koole, Simone N.; Schagen van Leeuwen, Jules H.; Schreuder, Hendrik W.R.; Hermans, Ralph H.M.; de Hingh, Ignace H.J.T.; van Gent, Mignon D.J.M.; Arts, Henriëtte J.G.; van Ham, Maaike A.P.C.; van Dam, Peter A.; Vuylsteke, Peter; Aalbers, Arend G.J.; Verwaal, Victor J.; Van de Vijver, Koen K.; Aaronson, Neil K.; Sonke, Gabe S.; van Driel, Willemien J.
  • imprint: Ovid Technologies (Wolters Kluwer Health), 2024
  • Published in: Obstetrical & Gynecological Survey
  • Language: English
  • DOI: 10.1097/01.ogx.0001008536.08634.9f
  • ISSN: 1533-9866; 0029-7828
  • Keywords: Obstetrics and Gynecology ; General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>(Abstracted from <jats:italic toggle="yes">Lancet Oncol</jats:italic> 2023;24:P1109–P1118)</jats:p> <jats:p>Although the 5-year survival of patients with advanced ovarian cancer has improved, overall survival at 10 years remains approximately 13%. Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the delivery of chemotherapeutic agents directly into the peritoneum in combination with hyperthermia, which enhances penetration and increases sensitivity to platinum compounds by inducing a transient state of homologous recombination deficiency.</jats:p>